Camford Capital
VC Fund
Palo Alto, United States
Camford Capital is a venture capital firm that invests in Enterprise, Consumer, FinTech, and Healthcare companies.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Camford Capital invests in
Stages Camford Capital invests in
Countries Camford Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Poorya Hosseini
|
|||
Investment Focus
Industry
- Biotechnology 5 (50%)
- Therapeutics 3 (30%)
- Artificial Intelligence 3 (30%)
- Medical 1 (10%)
- Oncology 1 (10%)
Stage
- Seed 4 (40%)
- Series A 4 (40%)
- Series B 2 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ali Farahanchi
Partner
|
Partner | Total investments: 2 | Find email | |
|
Poorya Hosseini
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Totus Medicines
|
Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously untreatable diseases across the entire human genome. | $66M / Series B / Dec 15, 2023 | |
SURGE Therapeutics
|
SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. | $32M / Series B / Jul 19, 2023 | |
Lavita
|
Lavita is a blockchain-AI based next generation healthcare platform, enabling the use of massive biomedical datasets for research while preserving individual privacy and ownership of data. | $5M / Seed / May 10, 2023 | |
FEDML
|
FedML, Inc. (https://fedml.ai) provides an end-to-end machine learning operating system for people or organizations to transform their data to intelligence with minimum efforts. FedML stands for “Fundamental Ecosystem Development/Design for Machine Learning” in a broad scope, and “Federated Machine Learning” in a specific scope. Atthe current stage, FedML is developing and maintaining a machine learning platform that enables zero-code, lightweight, cross-platform, and provably secure federated learning and analytics. It enables machine learning from decentralized data at various users/silos/edge nodes, without the need to centralize any data to the cloud, hence providing maximum privacy and efficiency. It consists of a lightweight and cross-platform Edge AI SDK that is deployable over edge GPUs, smartphones, and IoT devices. Furthermore, it also provides a user-friendly MLOps platform to simplify decentralized machine learning and real-world deployment. FedML supports vertical solutions across a broad range of industries (healthcare, finance, insurance, smart cities, IoT, etc.) and applications (computer vision, natural language processing, data mining, and time-series forecasting). FedML also manages a vibrant open-source community/ecosystem on Federated Machine Learning with more than 1000 users worldwide. | $6M / Seed / Mar 28, 2023 | |
|
TensorOpera
|
TensorOpera, Inc. is an innovative AI company based in Silicon Valley, specifically Palo Alto, California. We specialize in developing scalable and secure AI platforms tailored for enterprises and developers. Its flagship products include: TensorOpera® AI Platform: Accessible at TensorOpera.ai, this platform serves as a comprehensive generative AIecosystem. It features robust tools for enterprise AI platforms, model deployment, model serving, AI agent APIs, and more. It supports launching training and inference jobs on a serverless/decentralized GPU cloud, experimental tracking for distributed training, and enhanced security and privacy measures. TensorOpera® FedML: Available at FedML.ai, this platform is a leader in federated learning and analytics, supporting zero-code implementation. It includes a lightweight, cross-platform Edge AI SDK suitable for edge GPUs, smartphones, and IoT devices. Additionally, it offers a user-friendly MLOps platform to streamline decentralized machine learning and deployment in real-world applications. | $6M / Seed / Mar 28, 2023 | |
Tahoe Therapeutics
|
Tahoe Therapeutics develops AI-powered tools to simulate human cell responses and guide drug discovery. It operates a platform called Mosaic that produces large-scale single-cell datasets detailing how drug molecules interact with diverse patient cells, with initial applications in oncology. It open-sources its Tahoe-100M dataset, comprisinghundreds of millions of single-cell profiles, to train AI models that build virtual cell models for therapeutic insights. A recent funding round enabled the creation of an even larger dataset, targeting one billion cell datapoints and one million drug-patient interactions, designed to fuel next-generation precision medicines | $12M / Seed / Dec 08, 2022 | |
|
SURGE Therapeutics
|
SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. | $26M / Series A / Oct 17, 2022 | |
Carbon Biosciences
|
Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities. | $38M / Series A / Jun 21, 2022 | |
|
Totus Medicines
|
Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously untreatable diseases across the entire human genome. | $40M / Series A / Dec 09, 2021 | |
Strand Therapeutics
|
Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer. | $52M / Series A / Jun 23, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Camford Capital invest in?
Camford Capital invests primarily in Biotechnology, Therapeutics and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Camford Capital?
Public channels for Camford Capital include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Camford Capital?
The team at Camford Capital includes Ali Farahanchi (Partner) and Poorya Hosseini (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
